Prevention and Control of Influenza, Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Nicole M. Smith, PhD; Joseph S. Bresee, MD; David K. Shay, MD; Timothy M. Uyeki, MD; Nancy J. Cox, PhD; Raymond A. Strikas, MD

Disclosures

Morbidity and Mortality Weekly Report. 2006;55(27):1-41. 

In This Article

Cost-Effectiveness of Influenza Vaccine

Influenza vaccination can reduce both health-care costs and productivity losses associated with influenza illness. Studies of influenza vaccination of persons aged ≥65 years conducted in the United States have reported substantial reductions in hospitalizations and deaths and overall societal costs savings.[15,100,104] Studies of adults aged <65 years have indicated that vaccination can reduce both direct medical costs and indirect costs from work absenteeism.[8,10,11,12,91,116] Reductions of 13%-44% in health-care-provider visits, 18%-45% in lost workdays, 18%-28% in days working with reduced effectiveness, and 25% in antibiotic use for influenza-associated illnesses have been reported.[10,12,117,118] One cost-effectiveness analysis estimated a cost of approximately $60-$4,000/illness averted among healthy persons aged 18-64 years, depending on the cost of vaccination, the influenza attack rate, and vaccine effectiveness against influenza-like illness (ILI).[91] Another cost-benefit economic study estimated an average annual savings of $13.66/person vaccinated.[119] In the second study, 78% of all costs prevented were costs from lost work productivity, whereas the first study did not include productivity losses from influenza illness.

Economic studies specifically evaluating the cost-effectiveness of vaccinating persons aged 50-64 years are not available, and the number of studies that examine the economics of routinely vaccinating children with TIV or LAIV are limited.[8,120,121,122,123] However, in a study of inactivated vaccine that included all age groups, cost utility (i.e., cost per year of healthy life gained) improved with increasing age and among those with chronic medical conditions.[8] Among persons aged ≥65 years, vaccination resulted in a net savings per quality-adjusted life year (QALY) gained, whereas among younger age groups, vaccination resulted in costs of $23-$256/QALY.

In addition to estimating the economic cost associated with influenza disease, studies have assessed the public's perception of preventing influenza morbidity. Less than half of respondents to a survey on public perception of the value of preventing influenza morbidity reported that they would trade any time from their own life to prevent a case of uncomplicated influenza in a hypothetical child.[124] When asked about their willingness to pay to prevent a hypothetical child from having an uncomplicated case of influenza, the median willingness-to-pay amount was $100 for a child aged 14 years and $175 for a child aged 1 year.[124]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....